参考文献:1. Laczkovics A, Havel M, Laufer G, Teufelsbauer H, Gollner C, Wolner E (1987) Orthotopic heart transplantation -experiences at the University Surgical Clinic II in Vienna (status: June 1986). Wien Klin Wochenschr 99(10): 333-0 2. Woloszczuk W, Schwarz M, Havel M, Laczkovics A, Müller MM (1986) Neopterin and interferon gamma serum levels in patients with heart and kidney transplants. J Clin Chem Clin Biochem 24 (10): 729-4 3. Hamilton G, Roth E, Mühlbacher F, Funovics J, Piza F, Schindler J, et al (1986) Measuring cyclosporin in immunosuppressive treatment following liver and heart transplantation. Wien Klin Wochenschr 98 (24): 820- 4. Havel MP, Laczkovics AM, Kurz RW, Müller MM, Wolner E (1987) Neopterin as a parameter for the early detection of acute graft rejection following heart transplantation. Z Med Lab Diagn 28 (8): 429-35 5. Hamilton G, Mühlbacher F, Roth E, Wolf I, Piza F, Havel M, et al (1987) Comparison of cyclosporine A dosage and metabolism in liver and heart transplant recipients. Transplant Proc 19 (1 Pt 2): 1706- 6. Trubel W, Losert U, Schima H, Rokitansky A, Spiss CK, Coraim F, et al (1987) Total artificial heart bridging: a temporary support for deteriorating heart transplantation-candidates -methods and results. Thorac Cardiovasc Surg 35 (5): 277-2 7. Laufer G, Laczkovics A, Wollenek G, Schreiner W, Wolner E (1988) Results of orthotopic heart transplantation with and without the use of maintenance steroids. Eur J Cardiothorac Surg 2 (4): 237-3 CrossRef 8. Laufer G, Laczkovics A, Wollenek G, Schreiner W, Kober I, Wolner E (1988) Incidence and severity of acute cardiac allograft rejection with two different low-dose cyclosporine maintenance protocols. Ann Thorac Surg 46 (4): 382- CrossRef 9. Wollenek G, Laufer G, Laczkovics A, Buxbaum P, Kober I (1989) Comparison of a monoclonal anti-T cell antibody vs ATG as prophylaxis after heart transplantation. Transplant Proc 21 (1 Pt 3): 2499-01 10. Laufer G, Laczkovics A, Wollenek G, Schreiner W, Sochor H, Holzinger C, et al (1989) Impacts of low-dose steroids and prophylactic monoclonal versus polyclonal antibodies on acute rejection in cyclosporine- and azathioprine-immunosuppressed cardiac allografts. J Heart Transplant 8 (3): 253-1 11. Laufer G, Miholic J, Laczkovics A, Wollenek G, Holzinger C, Hajek-Rosenmeier A, et al (1989) Independent risk factors predicting acute graft rejection in cardiac transplant recipients treated by triple drug immunosuppression. J Thorac Cardiovasc Surg 98 (6): 1113-1 12. Laufer G, Laczkovics A, Wollenek G, Buxbaum P, Seitelberger R, Holzinger C, et al (1991) The progression of mild acute cardiac rejection evaluated by risk factor analysis. The impact of maintenance steroids and serum creatinine. Transplantation 51 (1): 184- CrossRef 13. Laufer G, Laczkovics A, Wollenek G, Buxbaum P, Graninger W, Holzinger C, et al (1989) Infectious complications in heart transplant recipients with combined low dose cyclosporine, azathioprine and prednisolone (triple drug) immunosuppression. Transplant Proc 21 (1 Pt 3): 2508-1 14. Havel MP, Laczkovics AM, Wolner E, Kurz RW, Popow-Kraupp T (1989) Prophylactic use of hyperimmunoglobulin for cytomegalovirus infection in heart transplantation. Clin Ther 11 (4): 472- 15. Holzinger C, Buxbaum P, Laczkovics A, Domanig E, Wolner E (1990) Infections in organ transplantations. Zentralbl Chir 115 (17): 1091- 16. Havel M, Teufelsbauer H, Laczkovics A, Kurz R, Wolner E (1990) Cytomegalovirus hyperimmunoglobulin prophylaxis in the prevention of cytomegalovirus infection in immunosuppressed heart transplant patients. Transplant Proc 22 (4): 1805- 17. Bunzel B, Grundb?ck A, Laczkovics A, Holzinger C (1990) Surgical success following heart transplantation in relation to preoperative status. Wien Klin Wochenschr 102 (13): 375- 18. Bunzel B, Grundb?ck A, Laczkovics A, Holzinger C, Teufelsbauer H (1991) Quality of life after orthotopic heart transplantation. J Heart Lung Transplant 10 (3): 455- 19. H?lzel WG, Havel M, Laczkovics A, Müller MM (1988) Diagnostic validity of multivariate combinations of biochemical analytes as markers for rejection and infection in the follow-up of patients with heart transplants. J Clin Chem Clin Biochem 26 (11): 667-1 20. Havel M, Laczkovics A, Teufelsbauer H, Müller MM, Wolner E (1989) Neopterin as a new marker to detect acute rejection after heart transplantation. J Heart Transplant 8 (2): 167-0 21. Teufelsbauer H, Prischl FC, Havel M, Holzinger C, Lion T, Schwarzmeier JD, et al (1989) Beta 2-microglobulin. A reliable parameter for differentiating between graft rejection and severe infection after cardiac transplantation. Circulation 80 (6): 1681- 22. Holzinger C, Zuckermann A, Laczkovics A, Seitelberger R, Laufer G, Andert S, Kink F, Horvart R, Wolner E (1991) Monitoring of mononuclear cell subsets isolated from the coronary sinus and the right atrium in patients after heart allograft transplantation. J Thorac Cardiovasc Surg 102 (2): 215-2; discussion 223 23. Schreiner W, Lahoda R, Laufer G, Premauer W, Merksa F, Zahradnik D, et al (1990) Analysis of the ECG in diagnosis of graft rejection following heart Transplantation. Biomed Tech (Berl) 35 [Suppl 2]: 75- CrossRef 24. Heinz G, Ohner T, Laufer G, Gasic S, Laczkovics A (1990) Clinical and electrophysiologic correlates of sinus node dysfunction after orthotopic heart transplantation. Observations in 42 patients. Chest 97 (4): 890- CrossRef 25. Heinz G, Laufer G, Ohner T, Gasic S, Laczkovics A (1990) Analysis of heart rate changes in cardiac transplant recipients related to graft rejection. Am J Cardiol 66 (5): 647- CrossRef 26. Heinz G, Ohner T, Laufer G, G?ssinger H, Gasic S, Laczkovics A (1991) Demographic and perioperative factors associated with initial and prolonged sinus node dysfunction after orthotopic heart transplantation. The impact of ischemic time. Transplantation 51 (6): 1217-4 CrossRef 27. Schreiner W, Laufer G, Neumann M, Lahoda R, Premauer W, Merksa F, et al (1991) A beat-by-beat analysis of electrocardiograms from cardiac transplant recipients. J Biomed Eng 13 (4): 313-0 CrossRef 28. Grimm M, Grimm G, Zuckermann A, Wieselthaler G, Daneschvar H, Kocher A, et al (1995) Strategies in management of heart transplantation candidates with tachycardic ventricular arrhythmia anamnesis. Wien Klin Wochenschr 107 (16): 479-4 29. Grimm M, Grimm G, Zuckermann A, Wieselthaler G, Feuerstein M, Daneschvar H, et al (1995) ICD therapy in survivors of sudden cardiac death awaiting heart transplantation. Ann Thorac Surg 59 (4): 916-0 CrossRef 30. Grimm M, Wieselthaler G, Avanessian R, Grimm G, Schmidinger H, Schreiner W, et al (1995) The impact of implantable cardioverter-defibrillators on mortality among patients on the waiting list for heart transplantation. J Thorac Cardiovasc Surg 110 (2): 532- CrossRef 31. Daneschvar H, Pacher R, R?dler S, Stanek B, Hülsmann M, Grimm M, et al (1996) Acceptance of a pump-driven infusion therapy with prostaglandin E1 as a bridge to heart transplantation. Wien Klin Wochenschr 108 (16): 510- 32. Pacher R, Stanek B, Hülsmann M, Berger R, Siegel A, Daneschvar H, et al (1997) Prostaglandin E1 -bridge to cardiac transplantation. Technique, dosage, results. Eur Heart J 18 (2): 318-9 33. Stanek B, Sturm B, Frey B, Hülsmann M, Bojic A, Berger R, et al (1999) Bridging to heart transplantation: prostaglandin E1 versus prostacyclin versus dobutamine. J Heart Lung Transplant 18 (4): 358-6 CrossRef 34. Kratochwill C, Schmid S, Koller-Strametz J, Kreiner G, Grabenw?ger M, Grimm M, et al (1996) Decrease in pacemaker incidence after orthotopic heart transplantation. Am J Cardiol 77 (9): 779-3 CrossRef 35. Koller-Strametz J, Kratochwill C, Grabenw?ger M, Laufer G, Pacher R, Gemeiner N, et al (1997) PR interval adaptation in the denervated transplanted heart. Pacing Clin Electrophysiol 20 (5 Pt 1): 1247-1 CrossRef 36. Heinz G, Kratochwill C, Koller-Strametz J, Kreiner G, Grimm M, Grabenw?ger M, et al (1998) Benign prognosis of early sinus node dysfunction after orthotopic cardiac transplantation. Pacing Clin Electrophysiol 21 (2): 422- CrossRef 37. Klappacher G, Mehrabi M, Franzen P, Plesch K, Binder M, Haab D, et al (1994) Endomyocardial HLA expression is increased to the same extent in idiopathic and secondary dilated cardiomyopathy. Immunol Lett 41 (1): 59-6 CrossRef 38. Holzinger C, Zuckermann A, Reinwald C, Imhof M, Sch?llhammer A, Kramer, et al (1996) Are T cells from healthy heart really only passengers? Characterization of cardiac tissue T cells. Immunol Lett 53 (2-): 63- CrossRef 39. Baumgartner H, Porenta G, Lau YK, Wutte M, Klaar U, Mehrabi M, et al (1998) Assessment of myocardial viability by dobutamine echocardiography, positron emission tomography and thallium-201 SPECT: correlation with histopathology in explanted hearts. J Am Coll Cardiol 32 (6): 1701- CrossRef 40. Vogl M, Griesmacher A, Grimm M, Klepetko W, Müller MM (1995) Tissue polypeptide specific antigen for the detection of lymphoproliferative diseases induced by cyclosporin. J Clin Pathol 48 (11): 1039-4 CrossRef 41. Grimm M, Yeganehfar W, Laufer G, Madl C, Kramer L, Eisenhuber E, et al (1996) Cyclosporine may affect improvement of cognitive brain function after successful cardiac transplantation. Circulation 94 (6): 1339-5 42. Griesmacher A, Weigel G, Seebacher G, Mallinger R, Laufer G, Müller MM (1998) Inhibition of inosine monophosphate dehydrogenase activity by the plasma of heart transplant recipients receiving mycophenolate mofetil. Adv Exp Med Biol 431: 537-1 43. Seebacher G, Mallinger R, Laufer G, Grimm M, Griesmacher A, Weigel G, et al (1998) Pharmacokinetics of mycophenolate mofetil in heart transplant recipients. Adv Exp Med Biol 431: 801- 44. Seebacher G, Weigel G, Griesmacher A, Mallinger R, Zuckermann A, Grimm M, et al (1999) One and a half years of experience with mycophenolate mofetil (Cellcept) in cardiac transplantation: a prospective, randomized study. Transplant Proc 31 (8): 3291- CrossRef 45. Müller TF, Vogl M, Neumann MC, Lange H, Grimm M, Müller MM (1998) Noninvasive monitoring using serum amyloid A and serum neopterin in cardiac transplantation. Clin Chim Acta 276 (1): 63-4 CrossRef 46. Moidl R, Chevtchik O, Simon P, Grimm M, Wieselthaler G, Ullrich R, et al (1999) Noninvasive monitoring of peak filling rate with acoustic quantification echocardiography accurately detects acute cardiac allograft rejection. J Heart Lung Transplant 18 (3): 194-01 CrossRef 47. Eisen HJ, Hobbs RE, Davis SF, Laufer G, Mancini DM, Renlund DG, et al (1999) Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine -results at six months after transplantation. Transplantation 68 (5): 663-1 CrossRef 48. Eisen HJ, Hobbs RE, Davis SF, Carrier M, Mancini DM, Smith A, et al (2001) Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine -results at 24 months after transplantation. Transplantation 71 (1): 70- CrossRef 49. Grasser B, Iberer F, Schreier G, Kastner P, Schaffellner S, Kniepeiss D, et al (2003) Computerized heart allograft-recipient monitoring: a multicenter study. Transpl Int 16 (4): 225-0 CrossRef 50. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler H, et al (2003) Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 (9): 847-8 CrossRef 51. Podesser BK, Rinaldi M, Yona NA, Pulpón LA, Villemot JP, Haverich A, et al (2005) Comparison of low and high initial tacrolimus dosing in primary heart transplant recipients: a prospective European multicenter study. Transplantation 79 (1): 65-1 CrossRef 52. Grimm M, Rinaldi M, Yonan NA, Arpesella G, Arizón Del Prado, et al (2006) Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients -a large European trial. Am J Transplant 6 (6): 1387-7 CrossRef 53. Zuckermann AO, Ofner P, Holzinger C, Grimm M, Mallinger R, Laufer G, et al (2000) Pre- and early postoperative risk factors for death after cardiac transplantation: a single center analysis. Transpl Int 13 (1): 28-4 54. Zuckermann AO, Grimm M, Czerny M, Ofner P, Ullrich R, Ploner M, et al (2000) Improved long-term results with thymoglobuline induction therapy after cardiac transplantation: a comparison of two different rabbit-antithymocyte globulines. Transplantation 69 (9): 1890- CrossRef 55. Zuckermann A, Ploner M, Czerny M, Keziban U, Birsan T, Laufer G, et al (2002) Low incidence of graft arteriosclerosis after cardiac transplantation: risk factor analysis for patients with induction therapy. Transplant Proc 34 (5): 1869-1 CrossRef 56. Wexberg P, Pacher R, R?dler S, Kiss K, Beran G, Grimm M, et al (2002) Intimal hyperplasia and coronary flow reserve after heart transplantation: association with big endothelin-1. J Heart Lung Transplant 21 (12): 1257-3 CrossRef 57. Kocher AA, Bonaros N, Dunkler D, Ehrlich M, Schlechta B, Zweytick B, et al (2003) Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients. J Heart Lung Transplant 22 (3): 250- CrossRef 58. Zuckermann A, Dunkler D, Deviatko E, Bodhjalian A, Czerny M, Ankersmit J, et al (2003) Long-term survival (> 10 years) of patients > 60 years with induction therapy after cardiac transplantation. Eur J Cardiothorac Surg 24 (2): 283-1 CrossRef 59. Starling RC, Pham M, Valantine H, Miller L, Eisen H, et al (2006) Working Group on Molecular Testing in Cardiac Transplantation. Molecular testing in the management of cardiac transplant recipients: initial clinical experience. J Heart Lung Transplant 25 (12): 1389-5 CrossRef 60. Meyer B, Moertl D, Huelsmann M, Kulemann V, Zuckermann A, Grimm M, et al (2006) Heart transplantation provides long-term survival benefit in stable patients experiencing heart failure without reverse left ventricular remodeling. Transplantation 82 (11): 1463-1 CrossRef 61. Taghavi S, Zuckermann A, Ankersmit J, Wieselthaler G, Rajek A, Laufer G, et al (2004) Extracorporeal membrane oxygenation is superior to right ventricular assist device for acute right ventricular failure after heart transplantation. Ann Thorac Surg 78 (5): 1644- CrossRef 62. Aharinejad S, Sch?fer R, Hofbauer R, Abraham D, Blumer R, Miksovsky A, et al (2001) Impact of cardiac transplantation on molecular pathology of ET-1, VEGF-C, and mitochondrial metabolism and morphology in dilated versus ischemic cardiomyopathic patients. Transplantation 72 (6): 1043- CrossRef 63. Aharinejad S, Abraham D, Paulus P, Zins K, Hofmann M, Michlits W, et al (2008) Colony-stimulating factor-1 transfection of myoblasts improves the repair of failing myocardium following autologous myoblast transplantation. Cardiovasc Res 79 (3): 395-04 CrossRef 64. Aharinejad S, Andrukhova O, Lucas T, Zuckermann A, Wieselthaler G, Wolner E, et al (2008) Programmed cell death in idiopathic dilated cardiomyopathy is mediated by suppression of the apoptosis inhibitor Apollon. Ann Thorac Surg 86 (1): 109-4 CrossRef 65. Aharinejad S, Sch?fer R, Krenn K, Zuckermann A, Schneider B, Neumann F, et al (2007) Donor myocardial HIF-1alpha is an independent predictor of cardiac allograft dysfunction: a 7-year prospective, exploratory study. Am J Transplant 7 (8): 2012- CrossRef 66. Aharinejad S, Krenn K, Paulus P, Sch?fer R, Zuckermann A, Grimm M, et al (2005) Differential role of TGF-beta1/bFGF and ET-1 in graft fibrosis in heart failure patients. Am J Transplant 5 (9): 2185-2 CrossRef 67. Valantine H, Zuckermann A (2005) From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation. J Heart Lung Transplant 24 [4 Suppl]: S185-0 CrossRef 68. Devyatko E, Zuckermann A, Bohdjalian A, Roedler S, Dunkler D, Grimm M, et al (2006) Activation of the purine salvage pathway in mononuclear cells of cardiac recipients treated with mycophenolate mofetil. Transplantation 82 (1): 113- CrossRef 69. Aliabadi AZ, Zuckermann AO, Grimm M (2007) Immunosuppressive therapy in older cardiac transplant patients. Drugs Aging 24 (11): 913-2 CrossRef 70. Rothenburger M, Zuckermann A, Bara C, Hummel M, Strüber M, Hirt, et al (2007) Certican Consensus Study Group. Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference. J Heart Lung Transplant 26 (4): 305-1 CrossRef 71. Chapman JR, Valantine H, Albanell J, Arns WA, Campistol JM, Eisen H, et al (2007) Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 39 (10): 2937-0 CrossRef 72. Aliabadi AZ, Pohanka E, Seebacher G, Dunkler D, Kammerst?tter D, Wolner E, et al (2008) Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. Am J Transplant 8 (4): 854-1 CrossRef 73. Zuckermann A, Manito N, Epailly E, Fiane A, Bara C, Delgado JF, et al (2008) Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 27 (2): 141- CrossRef 74. Devyatko E, Dunkler D, Bohdjalian A, Zuckermann A, Grimm M, Muehlbacher F, et al (2008) Lymphocyte activation and correlation with IMPDH activity under therapy with mycophenolate mofetil. Clin Chim Acta 394 (1-): 67-1 CrossRef 75. Syeda B, Roedler S, Schukro C, Yahya N, Zuckermann A, Glogar D (2005) Transplant coronary artery disease: incidence, progression and interventional revascularization. Int J Cardiol 104 (3): 269-4 CrossRef 76. Ullrich R, Exner M, Schillinger M, Zuckermann A, Raith M, Dunkler D, et al (2005) Microsatellite polymorphism in the heme oxygenase-1 gene promoter and cardiac allograft vasculopathy. J Heart Lung Transplant 24 (10): 1600- CrossRef 77. Czerny M, Sahin V, Fasching P, Zuckermann A, Zimpfer D, Kilo, et al (2002) The impact of diabetes mellitus at the time of heart transplantation on long-term survival. Diabetologia 45 (11): 1498-08 CrossRef 78. Laufer G, Kocher A, Grabenwoger M, Berlakovich GA, Zuckermann A, Ofner P, et al (1997) Simultaneous heart and kidney transplantation as treatment for end-stage heart and kidney failure. Transplantation 64 (8): 1129-4 CrossRef 79. Gorlitzer M, Ankersmit J, Fiegl N, Meinhart J, Lanzenberger M, Unal K, et al (2005) Is the transpulmonary pressure gradient a predictor for mortality after orthotopic cardiac transplantation? Transpl Int 18 (4): 390- CrossRef 80. Zimpfer D, Zrunek P, Roethy W, Czerny M, Schima H, Huber L, et al (2007) Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates. J Thorac Cardiovasc Surg 133 (3): 689-5 CrossRef 81. Zuckermann A, Kocher A, Simon P, Ofner P, Grimm M, K?ck S, et al (1996) Expanding the donor pool in cardiac transplantation by accepting donor hearts > 40 years. Transplant Proc 28(1): 179-0 82. Billingham ME, Cary NR, Hammond ME, et al (1990) A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 9 (6): 587-3
作者单位:Andreas Zuckermann (A1) Arezu Aliabadi (A1) Daniela Dunkler (A1) Stephane Mahr (A1) Martina Gr?mmer (A1) Daniel Zimpfer (A1) Brigitte Bunzel (A1) Angela Rajek (A1) Georg Wieselthaler (A1) Martin Hülsmann (A1) Richard Pacher (A1) Gregor Wollenek (A1) Günter Weigel (A1) Ulrike Salzer-Muhar (A1) Axel Laczkovics (A1) Günther Laufer (A1) Michael Grimm (A1) Ernst Wolner (A1)
A1. Department of Cardio-Thoracic Surgery, Department of Cardio-Thoracic Anesthesiology and Intensive Care, Department of Cardiology, Department of Pediatric Cardiology, Medical University of Vienna, Austria